Candida infection is a yeast infection where the skin acts as a host organism, and the infection multiplies and grows with the period. Candida albicans are the most common species of this infection. Candida normally lives on the skin and inside the body, such as the throat, gut, mouth, and vagina, without causing problems. It can cause infections if it grows out of control or enters deep into the body.

The global Candida Infections Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Candida Infections Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Candida Infections Drugs.

Report Scope

The Candida Infections Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Candida Infections Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Candida Infections Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Candida Infections Drugs Market Report

Report Metric	Details
Report Name	Candida Infections Drugs Market
CAGR	5%
Segment by Type	Azole Nystatin Other
Segment by Application	Beriberi Jock Itch Vaginal Infection Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	F. Hoffmann-La Roche Ltd, Mylan NV, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GSK plc, Novartis AG, AstraZeneca, Johnson & Johnson Private Limited, Sun Pharmaceutical Industries Ltd, Merck & Co., Inc, Bristol-Myers Squibb Company, Lilly, Amgen Inc
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Candida Infections Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Candida Infections Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Candida Infections Drugs Market report?

Ans: The main players in the Candida Infections Drugs Market are F. Hoffmann-La Roche Ltd, Mylan NV, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GSK plc, Novartis AG, AstraZeneca, Johnson & Johnson Private Limited, Sun Pharmaceutical Industries Ltd, Merck & Co., Inc, Bristol-Myers Squibb Company, Lilly, Amgen Inc

What are the Application segmentation covered in the Candida Infections Drugs Market report?

Ans: The Applications covered in the Candida Infections Drugs Market report are Beriberi, Jock Itch, Vaginal Infection, Other

What are the Type segmentation covered in the Candida Infections Drugs Market report?

Ans: The Types covered in the Candida Infections Drugs Market report are Azole, Nystatin, Other

1 Candida Infections Drugs Market Overview

1.1 Product Overview and Scope of Candida Infections Drugs

1.2 Candida Infections Drugs Segment by Type

1.2.1 Global Candida Infections Drugs Market Value Comparison by Type (2024-2030)

1.2.2 Azole

1.2.3 Nystatin

1.2.4 Other

1.3 Candida Infections Drugs Segment by Application

1.3.1 Global Candida Infections Drugs Market Value by Application: (2024-2030)

1.3.2 Beriberi

1.3.3 Jock Itch

1.3.4 Vaginal Infection

1.3.5 Other

1.4 Global Candida Infections Drugs Market Size Estimates and Forecasts

1.4.1 Global Candida Infections Drugs Revenue 2019-2030

1.4.2 Global Candida Infections Drugs Sales 2019-2030

1.4.3 Global Candida Infections Drugs Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Candida Infections Drugs Market Competition by Manufacturers

2.1 Global Candida Infections Drugs Sales Market Share by Manufacturers (2019-2024)

2.2 Global Candida Infections Drugs Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Candida Infections Drugs Average Price by Manufacturers (2019-2024)

2.4 Global Candida Infections Drugs Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Candida Infections Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Candida Infections Drugs, Product Type & Application

2.7 Candida Infections Drugs Market Competitive Situation and Trends

2.7.1 Candida Infections Drugs Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Candida Infections Drugs Players Market Share by Revenue

2.7.3 Global Candida Infections Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Candida Infections Drugs Retrospective Market Scenario by Region

3.1 Global Candida Infections Drugs Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Candida Infections Drugs Global Candida Infections Drugs Sales by Region: 2019-2030

3.2.1 Global Candida Infections Drugs Sales by Region: 2019-2024

3.2.2 Global Candida Infections Drugs Sales by Region: 2025-2030

3.3 Global Candida Infections Drugs Global Candida Infections Drugs Revenue by Region: 2019-2030

3.3.1 Global Candida Infections Drugs Revenue by Region: 2019-2024

3.3.2 Global Candida Infections Drugs Revenue by Region: 2025-2030

3.4 North America Candida Infections Drugs Market Facts & Figures by Country

3.4.1 North America Candida Infections Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Candida Infections Drugs Sales by Country (2019-2030)

3.4.3 North America Candida Infections Drugs Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Candida Infections Drugs Market Facts & Figures by Country

3.5.1 Europe Candida Infections Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Candida Infections Drugs Sales by Country (2019-2030)

3.5.3 Europe Candida Infections Drugs Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Candida Infections Drugs Market Facts & Figures by Country

3.6.1 Asia Pacific Candida Infections Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Candida Infections Drugs Sales by Country (2019-2030)

3.6.3 Asia Pacific Candida Infections Drugs Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Candida Infections Drugs Market Facts & Figures by Country

3.7.1 Latin America Candida Infections Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Candida Infections Drugs Sales by Country (2019-2030)

3.7.3 Latin America Candida Infections Drugs Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Candida Infections Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Candida Infections Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Candida Infections Drugs Sales by Country (2019-2030)

3.8.3 Middle East and Africa Candida Infections Drugs Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Candida Infections Drugs Sales by Type (2019-2030)

4.1.1 Global Candida Infections Drugs Sales by Type (2019-2024)

4.1.2 Global Candida Infections Drugs Sales by Type (2025-2030)

4.1.3 Global Candida Infections Drugs Sales Market Share by Type (2019-2030)

4.2 Global Candida Infections Drugs Revenue by Type (2019-2030)

4.2.1 Global Candida Infections Drugs Revenue by Type (2019-2024)

4.2.2 Global Candida Infections Drugs Revenue by Type (2025-2030)

4.2.3 Global Candida Infections Drugs Revenue Market Share by Type (2019-2030)

4.3 Global Candida Infections Drugs Price by Type (2019-2030)

5 Segment by Application

5.1 Global Candida Infections Drugs Sales by Application (2019-2030)

5.1.1 Global Candida Infections Drugs Sales by Application (2019-2024)

5.1.2 Global Candida Infections Drugs Sales by Application (2025-2030)

5.1.3 Global Candida Infections Drugs Sales Market Share by Application (2019-2030)

5.2 Global Candida Infections Drugs Revenue by Application (2019-2030)

5.2.1 Global Candida Infections Drugs Revenue by Application (2019-2024)

5.2.2 Global Candida Infections Drugs Revenue by Application (2025-2030)

5.2.3 Global Candida Infections Drugs Revenue Market Share by Application (2019-2030)

5.3 Global Candida Infections Drugs Price by Application (2019-2030)

6 Key Companies Profiled

6.1 F. Hoffmann-La Roche Ltd

6.1.1 F. Hoffmann-La Roche Ltd Corporation Information

6.1.2 F. Hoffmann-La Roche Ltd Description and Business Overview

6.1.3 F. Hoffmann-La Roche Ltd Candida Infections Drugs Sales, Revenue and Gross Margin (2019-2024)

6.1.4 F. Hoffmann-La Roche Ltd Candida Infections Drugs Product Portfolio

6.1.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates

6.2 Mylan NV

6.2.1 Mylan NV Corporation Information

6.2.2 Mylan NV Description and Business Overview

6.2.3 Mylan NV Candida Infections Drugs Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Mylan NV Candida Infections Drugs Product Portfolio

6.2.5 Mylan NV Recent Developments/Updates

6.3 Teva Pharmaceutical Industries Ltd

6.3.1 Teva Pharmaceutical Industries Ltd Corporation Information

6.3.2 Teva Pharmaceutical Industries Ltd Description and Business Overview

6.3.3 Teva Pharmaceutical Industries Ltd Candida Infections Drugs Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Teva Pharmaceutical Industries Ltd Candida Infections Drugs Product Portfolio

6.3.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates

6.4 Sanofi

6.4.1 Sanofi Corporation Information

6.4.2 Sanofi Description and Business Overview

6.4.3 Sanofi Candida Infections Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Sanofi Candida Infections Drugs Product Portfolio

6.4.5 Sanofi Recent Developments/Updates

6.5 Pfizer Inc

6.5.1 Pfizer Inc Corporation Information

6.5.2 Pfizer Inc Description and Business Overview

6.5.3 Pfizer Inc Candida Infections Drugs Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Pfizer Inc Candida Infections Drugs Product Portfolio

6.5.5 Pfizer Inc Recent Developments/Updates

6.6 GSK plc

6.6.1 GSK plc Corporation Information

6.6.2 GSK plc Description and Business Overview

6.6.3 GSK plc Candida Infections Drugs Sales, Revenue and Gross Margin (2019-2024)

6.6.4 GSK plc Candida Infections Drugs Product Portfolio

6.6.5 GSK plc Recent Developments/Updates

6.7 Novartis AG

6.6.1 Novartis AG Corporation Information

6.6.2 Novartis AG Description and Business Overview

6.6.3 Novartis AG Candida Infections Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Novartis AG Candida Infections Drugs Product Portfolio

6.7.5 Novartis AG Recent Developments/Updates

6.8 AstraZeneca

6.8.1 AstraZeneca Corporation Information

6.8.2 AstraZeneca Description and Business Overview

6.8.3 AstraZeneca Candida Infections Drugs Sales, Revenue and Gross Margin (2019-2024)

6.8.4 AstraZeneca Candida Infections Drugs Product Portfolio

6.8.5 AstraZeneca Recent Developments/Updates

6.9 Johnson & Johnson Private Limited

6.9.1 Johnson & Johnson Private Limited Corporation Information

6.9.2 Johnson & Johnson Private Limited Description and Business Overview

6.9.3 Johnson & Johnson Private Limited Candida Infections Drugs Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Johnson & Johnson Private Limited Candida Infections Drugs Product Portfolio

6.9.5 Johnson & Johnson Private Limited Recent Developments/Updates

6.10 Sun Pharmaceutical Industries Ltd

6.10.1 Sun Pharmaceutical Industries Ltd Corporation Information

6.10.2 Sun Pharmaceutical Industries Ltd Description and Business Overview

6.10.3 Sun Pharmaceutical Industries Ltd Candida Infections Drugs Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Sun Pharmaceutical Industries Ltd Candida Infections Drugs Product Portfolio

6.10.5 Sun Pharmaceutical Industries Ltd Recent Developments/Updates

6.11 Merck & Co., Inc

6.11.1 Merck & Co., Inc Corporation Information

6.11.2 Merck & Co., Inc Candida Infections Drugs Description and Business Overview

6.11.3 Merck & Co., Inc Candida Infections Drugs Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Merck & Co., Inc Candida Infections Drugs Product Portfolio

6.11.5 Merck & Co., Inc Recent Developments/Updates

6.12 Bristol-Myers Squibb Company

6.12.1 Bristol-Myers Squibb Company Corporation Information

6.12.2 Bristol-Myers Squibb Company Candida Infections Drugs Description and Business Overview

6.12.3 Bristol-Myers Squibb Company Candida Infections Drugs Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Bristol-Myers Squibb Company Candida Infections Drugs Product Portfolio

6.12.5 Bristol-Myers Squibb Company Recent Developments/Updates

6.13 Lilly

6.13.1 Lilly Corporation Information

6.13.2 Lilly Candida Infections Drugs Description and Business Overview

6.13.3 Lilly Candida Infections Drugs Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Lilly Candida Infections Drugs Product Portfolio

6.13.5 Lilly Recent Developments/Updates

6.14 Amgen Inc

6.14.1 Amgen Inc Corporation Information

6.14.2 Amgen Inc Candida Infections Drugs Description and Business Overview

6.14.3 Amgen Inc Candida Infections Drugs Sales, Revenue and Gross Margin (2019-2024)

6.14.4 Amgen Inc Candida Infections Drugs Product Portfolio

6.14.5 Amgen Inc Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Candida Infections Drugs Industry Chain Analysis

7.2 Candida Infections Drugs Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Candida Infections Drugs Production Mode & Process

7.4 Candida Infections Drugs Sales and Marketing

7.4.1 Candida Infections Drugs Sales Channels

7.4.2 Candida Infections Drugs Distributors

7.5 Candida Infections Drugs Customers

8 Candida Infections Drugs Market Dynamics

8.1 Candida Infections Drugs Industry Trends

8.2 Candida Infections Drugs Market Drivers

8.3 Candida Infections Drugs Market Challenges

8.4 Candida Infections Drugs Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

F Hoffmann La Roche Ltd

Mylan NV

Teva Pharmaceutical Industries Ltd

Johnson & Johnson Private Limited

Sun Pharmaceutical Industries Ltd.

Merck& Co. Inc

Bristol Myers Squibb Company

Lilly

Amgen Inc

List of Tables

Table 1. Global Candida Infections Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Candida Infections Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Candida Infections Drugs Market Competitive Situation by Manufacturers in 2023

Table 4. Global Candida Infections Drugs Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Candida Infections Drugs Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Candida Infections Drugs Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Candida Infections Drugs Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Candida Infections Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Candida Infections Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Candida Infections Drugs, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Candida Infections Drugs, Product Type & Application

Table 12. Global Key Manufacturers of Candida Infections Drugs, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Candida Infections Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Candida Infections Drugs as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Candida Infections Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Candida Infections Drugs Sales by Region (2019-2024) & (K Units)

Table 18. Global Candida Infections Drugs Sales Market Share by Region (2019-2024)

Table 19. Global Candida Infections Drugs Sales by Region (2025-2030) & (K Units)

Table 20. Global Candida Infections Drugs Sales Market Share by Region (2025-2030)

Table 21. Global Candida Infections Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Candida Infections Drugs Revenue Market Share by Region (2019-2024)

Table 23. Global Candida Infections Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Candida Infections Drugs Revenue Market Share by Region (2025-2030)

Table 25. North America Candida Infections Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Candida Infections Drugs Sales by Country (2019-2024) & (K Units)

Table 27. North America Candida Infections Drugs Sales by Country (2025-2030) & (K Units)

Table 28. North America Candida Infections Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Candida Infections Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Candida Infections Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Candida Infections Drugs Sales by Country (2019-2024) & (K Units)

Table 32. Europe Candida Infections Drugs Sales by Country (2025-2030) & (K Units)

Table 33. Europe Candida Infections Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Candida Infections Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Candida Infections Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Candida Infections Drugs Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Candida Infections Drugs Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Candida Infections Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Candida Infections Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Candida Infections Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Candida Infections Drugs Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Candida Infections Drugs Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Candida Infections Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Candida Infections Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Candida Infections Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Candida Infections Drugs Sales by Country (2019-2024) & (K Units)

Table 47. Middle East & Africa Candida Infections Drugs Sales by Country (2025-2030) & (K Units)

Table 48. Middle East & Africa Candida Infections Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Candida Infections Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Candida Infections Drugs Sales (K Units) by Type (2019-2024)

Table 51. Global Candida Infections Drugs Sales (K Units) by Type (2025-2030)

Table 52. Global Candida Infections Drugs Sales Market Share by Type (2019-2024)

Table 53. Global Candida Infections Drugs Sales Market Share by Type (2025-2030)

Table 54. Global Candida Infections Drugs Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Candida Infections Drugs Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Candida Infections Drugs Revenue Market Share by Type (2019-2024)

Table 57. Global Candida Infections Drugs Revenue Market Share by Type (2025-2030)

Table 58. Global Candida Infections Drugs Price (US$/Unit) by Type (2019-2024)

Table 59. Global Candida Infections Drugs Price (US$/Unit) by Type (2025-2030)

Table 60. Global Candida Infections Drugs Sales (K Units) by Application (2019-2024)

Table 61. Global Candida Infections Drugs Sales (K Units) by Application (2025-2030)

Table 62. Global Candida Infections Drugs Sales Market Share by Application (2019-2024)

Table 63. Global Candida Infections Drugs Sales Market Share by Application (2025-2030)

Table 64. Global Candida Infections Drugs Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Candida Infections Drugs Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Candida Infections Drugs Revenue Market Share by Application (2019-2024)

Table 67. Global Candida Infections Drugs Revenue Market Share by Application (2025-2030)

Table 68. Global Candida Infections Drugs Price (US$/Unit) by Application (2019-2024)

Table 69. Global Candida Infections Drugs Price (US$/Unit) by Application (2025-2030)

Table 70. F. Hoffmann-La Roche Ltd Corporation Information

Table 71. F. Hoffmann-La Roche Ltd Description and Business Overview

Table 72. F. Hoffmann-La Roche Ltd Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. F. Hoffmann-La Roche Ltd Candida Infections Drugs Product

Table 74. F. Hoffmann-La Roche Ltd Recent Developments/Updates

Table 75. Mylan NV Corporation Information

Table 76. Mylan NV Description and Business Overview

Table 77. Mylan NV Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Mylan NV Candida Infections Drugs Product

Table 79. Mylan NV Recent Developments/Updates

Table 80. Teva Pharmaceutical Industries Ltd Corporation Information

Table 81. Teva Pharmaceutical Industries Ltd Description and Business Overview

Table 82. Teva Pharmaceutical Industries Ltd Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Teva Pharmaceutical Industries Ltd Candida Infections Drugs Product

Table 84. Teva Pharmaceutical Industries Ltd Recent Developments/Updates

Table 85. Sanofi Corporation Information

Table 86. Sanofi Description and Business Overview

Table 87. Sanofi Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Sanofi Candida Infections Drugs Product

Table 89. Sanofi Recent Developments/Updates

Table 90. Pfizer Inc Corporation Information

Table 91. Pfizer Inc Description and Business Overview

Table 92. Pfizer Inc Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Pfizer Inc Candida Infections Drugs Product

Table 94. Pfizer Inc Recent Developments/Updates

Table 95. GSK plc Corporation Information

Table 96. GSK plc Description and Business Overview

Table 97. GSK plc Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. GSK plc Candida Infections Drugs Product

Table 99. GSK plc Recent Developments/Updates

Table 100. Novartis AG Corporation Information

Table 101. Novartis AG Description and Business Overview

Table 102. Novartis AG Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Novartis AG Candida Infections Drugs Product

Table 104. Novartis AG Recent Developments/Updates

Table 105. AstraZeneca Corporation Information

Table 106. AstraZeneca Description and Business Overview

Table 107. AstraZeneca Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. AstraZeneca Candida Infections Drugs Product

Table 109. AstraZeneca Recent Developments/Updates

Table 110. Johnson & Johnson Private Limited Corporation Information

Table 111. Johnson & Johnson Private Limited Description and Business Overview

Table 112. Johnson & Johnson Private Limited Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Johnson & Johnson Private Limited Candida Infections Drugs Product

Table 114. Johnson & Johnson Private Limited Recent Developments/Updates

Table 115. Sun Pharmaceutical Industries Ltd Corporation Information

Table 116. Sun Pharmaceutical Industries Ltd Description and Business Overview

Table 117. Sun Pharmaceutical Industries Ltd Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Sun Pharmaceutical Industries Ltd Candida Infections Drugs Product

Table 119. Sun Pharmaceutical Industries Ltd Recent Developments/Updates

Table 120. Merck & Co., Inc Corporation Information

Table 121. Merck & Co., Inc Description and Business Overview

Table 122. Merck & Co., Inc Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 123. Merck & Co., Inc Candida Infections Drugs Product

Table 124. Merck & Co., Inc Recent Developments/Updates

Table 125. Bristol-Myers Squibb Company Corporation Information

Table 126. Bristol-Myers Squibb Company Description and Business Overview

Table 127. Bristol-Myers Squibb Company Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 128. Bristol-Myers Squibb Company Candida Infections Drugs Product

Table 129. Bristol-Myers Squibb Company Recent Developments/Updates

Table 130. Lilly Corporation Information

Table 131. Lilly Description and Business Overview

Table 132. Lilly Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 133. Lilly Candida Infections Drugs Product

Table 134. Lilly Recent Developments/Updates

Table 135. Amgen Inc Corporation Information

Table 136. Amgen Inc Description and Business Overview

Table 137. Amgen Inc Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 138. Amgen Inc Candida Infections Drugs Product

Table 139. Amgen Inc Recent Developments/Updates

Table 140. Key Raw Materials Lists

Table 141. Raw Materials Key Suppliers Lists

Table 142. Candida Infections Drugs Distributors List

Table 143. Candida Infections Drugs Customers List

Table 144. Candida Infections Drugs Market Trends

Table 145. Candida Infections Drugs Market Drivers

Table 146. Candida Infections Drugs Market Challenges

Table 147. Candida Infections Drugs Market Restraints

Table 148. Research Programs/Design for This Report

Table 149. Key Data Information from Secondary Sources

Table 150. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Candida Infections Drugs

Figure 2. Global Candida Infections Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Candida Infections Drugs Market Share by Type in 2023 & 2030

Figure 4. Azole Product Picture

Figure 5. Nystatin Product Picture

Figure 6. Other Product Picture

Figure 7. Global Candida Infections Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 8. Global Candida Infections Drugs Market Share by Application in 2023 & 2030

Figure 9. Beriberi

Figure 10. Jock Itch

Figure 11. Vaginal Infection

Figure 12. Other

Figure 13. Global Candida Infections Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Candida Infections Drugs Market Size (2019-2030) & (US$ Million)

Figure 15. Global Candida Infections Drugs Sales (2019-2030) & (K Units)

Figure 16. Global Candida Infections Drugs Average Price (US$/Unit) & (2019-2030)

Figure 17. Candida Infections Drugs Report Years Considered

Figure 18. Candida Infections Drugs Sales Share by Manufacturers in 2023

Figure 19. Global Candida Infections Drugs Revenue Share by Manufacturers in 2023

Figure 20. The Global 5 and 10 Largest Candida Infections Drugs Players: Market Share by Revenue in 2023

Figure 21. Candida Infections Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 22. Global Candida Infections Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 23. North America Candida Infections Drugs Sales Market Share by Country (2019-2030)

Figure 24. North America Candida Infections Drugs Revenue Market Share by Country (2019-2030)

Figure 25. United States Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Canada Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. Europe Candida Infections Drugs Sales Market Share by Country (2019-2030)

Figure 28. Europe Candida Infections Drugs Revenue Market Share by Country (2019-2030)

Figure 29. Germany Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. France Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. U.K. Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Italy Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Russia Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Asia Pacific Candida Infections Drugs Sales Market Share by Region (2019-2030)

Figure 35. Asia Pacific Candida Infections Drugs Revenue Market Share by Region (2019-2030)

Figure 36. China Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Japan Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. South Korea Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. India Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Australia Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. China Taiwan Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Southeast Asia Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Latin America Candida Infections Drugs Sales Market Share by Country (2019-2030)

Figure 44. Latin America Candida Infections Drugs Revenue Market Share by Country (2019-2030)

Figure 45. Mexico Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Brazil Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Argentina Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Middle East & Africa Candida Infections Drugs Sales Market Share by Country (2019-2030)

Figure 49. Middle East & Africa Candida Infections Drugs Revenue Market Share by Country (2019-2030)

Figure 50. Turkey Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Saudi Arabia Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. UAE Candida Infections Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Global Sales Market Share of Candida Infections Drugs by Type (2019-2030)

Figure 54. Global Revenue Market Share of Candida Infections Drugs by Type (2019-2030)

Figure 55. Global Candida Infections Drugs Price (US$/Unit) by Type (2019-2030)

Figure 56. Global Sales Market Share of Candida Infections Drugs by Application (2019-2030)

Figure 57. Global Revenue Market Share of Candida Infections Drugs by Application (2019-2030)

Figure 58. Global Candida Infections Drugs Price (US$/Unit) by Application (2019-2030)

Figure 59. Candida Infections Drugs Value Chain

Figure 60. Candida Infections Drugs Production Process

Figure 61. Channels of Distribution (Direct Vs Distribution)

Figure 62. Distributors Profiles

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions